New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy

被引:133
作者
Beck, Michael [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Childrens Hosp, D-55101 Mainz, Germany
关键词
NIEMANN-PICK-DISEASE; MACROPHAGE-TARGETED GLUCOCEREBROSIDASE; NEURONOPATHIC GAUCHER-DISEASE; SUBSTRATE REDUCTION THERAPY; N-BUTYL-DEOXYNOJIRIMYCIN; FABRY-DISEASE; MOUSE MODEL; ALPHA-GLUCOSIDASE; METACHROMATIC LEUKODYSTROPHY; MUCOPOLYSACCHARIDOSIS-I;
D O I
10.1007/s00439-006-0280-4
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
During the last few years, much progress has been made in the treatment of lysosomal storage disorders. In the past, no specific therapy was available for the affected patients, and management consisted solely of supportive care and treatment of complications. Since enzyme replacement therapy has been successfully introduced for patients with Gaucher disease, this principle of treatment has been taken into consideration for other lysosomal storage disorders as well. Clinical trials could demonstrate the clinical benefit of this therapeutic principle in Fabry disease, mucopolysaccharidoses type I, II and VI and in Pompe disease. However, the usefulness of enzyme replacement therapy is limited due to the fact that a given enzyme preparation does not have beneficial effects on all aspects of a disorder in the same degree. Additionally, clinical studies have shown that many symptoms of a lysosomal storage disorder even after long-term treatment are no more reversible. A further novel therapeutic option for lysosomal storage disorders consists of the application of small molecules that either inhibit a key enzyme which is responsible for substrate synthesis (substrate deprivation) or act as a chaperone to increase the residual activity of the lysosomal enzyme (enzyme enhancing therapy). Various gene therapeutic techniques (in vivo and ex vivo technique) have been developed in order to administer the gene that is defective in a patient to the bloodstream or directly to the brain in order to overcome the blood-brain barrier. This review will give an insight into these newly developed therapeutic strategies and will discuss their advantages and limitations.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 122 条
[1]   The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease [J].
Altarescu, G ;
Hill, S ;
Wiggs, E ;
Jeffries, N ;
Kreps, C ;
Parker , CC ;
Brady, RO ;
Barton, NW ;
Schiffmann, R ;
Bannarjee, TK ;
Crutchfield, K ;
Frei, K ;
McKee, MA ;
Moore, DF ;
Tournay, A .
JOURNAL OF PEDIATRICS, 2001, 138 (04) :539-547
[2]   Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II:: Results of a phase I/II clinical trial [J].
Amalfitano, A ;
Bengur, AR ;
Morse, RP ;
Majure, JM ;
Case, LE ;
Veerling, DL ;
Mackey, J ;
Kishnani, P ;
Smith, W ;
McVie-Wylie, A ;
Sullivan, JA ;
Hoganson, GE ;
Phillips, JA ;
Schaefer, GB ;
Charrow, J ;
Ware, RE ;
Bossen, EH ;
Chen, YT .
GENETICS IN MEDICINE, 2001, 3 (02) :132-138
[3]   Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease [J].
An, Y ;
Young, SP ;
Kishnani, PS ;
Millington, DS ;
Amalfitano, A ;
Corzo, D ;
Chen, YT .
MOLECULAR GENETICS AND METABOLISM, 2005, 85 (04) :247-254
[4]   Individualization of long-term enzyme replacement therapy for Gaucher disease [J].
Andersson, HC ;
Charrow, J ;
Kaplan, P ;
Mistry, P ;
Pastores, GM ;
Prakesh-Cheng, A ;
Rosenbloom, BE ;
Scott, CR ;
Wappner, RS ;
Weinreb, NJ .
GENETICS IN MEDICINE, 2005, 7 (02) :105-110
[5]   Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb [J].
Aoki, M ;
Takahashi, Y ;
Miwa, Y ;
Iida, S ;
Sukegawa, K ;
Horai, T ;
Orii, T ;
Kondo, N .
EUROPEAN JOURNAL OF PEDIATRICS, 2001, 160 (01) :63-64
[6]  
Balfour-Lynn IM, 1998, PEDIATR PULM, V25, P278, DOI 10.1002/(SICI)1099-0496(199804)25:4<278::AID-PPUL8>3.0.CO
[7]  
2-G
[8]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE [J].
BARTON, NW ;
BRADY, RO ;
DAMBROSIA, JM ;
DIBISCEGLIE, AM ;
DOPPELT, SH ;
HILL, SC ;
MANKIN, HJ ;
MURRAY, GJ ;
PARKER, RI ;
ARGOFF, CE ;
GREWAL, RP ;
YU, KT .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1464-1470
[9]   Fabry disease: overall effects of agalsidase alfa treatment [J].
Beck, M ;
Ricci, R ;
Widmer, U ;
Dehout, F ;
de Lorenzo, AG ;
Kampmann, C ;
Linhart, A ;
Sunder-Plassmann, G ;
Houge, G ;
Ramaswami, U ;
Gal, A ;
Mehta, A .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (12) :838-844
[10]  
BECK M, 2005, EUR J HUM GENET, V13, P67